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Surgical Site Infection Reduction Through Nasal Decolonization Prior to Surgery
The Centers for Disease Control and Prevention define surgical site infection (SSI) as an
infection within 30 days after surgery without an implant and 90 days for patients with an
implant, and classify the infection as superficial, deep, or involving the surrounding area or
organ (Mockford and O’Grady, 2017). Surgical site infections occur in 2-5% of patients who
undergo surgery, and are currently the most common and expensive healthcare-acquired
infection in the United States (D. J. Anderson et al., 2014). Currently The Joint Commission
(2016) lists reducing and eliminating SSIs as a national patient safety goal. To meet this goal
hospitals employ many interventions. One of the recommended interventions to reduce SSIs is
to provide nasal decolonization for Staphylococcus aureus (S. aureus). In the summer of 2016,
the Clinical Nurse specialist from the Infection Control Department identified rising methicillinresistant Staphylococcus aureus (MRSA) surgical site infections as an opportunity to adopt new
interventions to improve rates in the medical center. The project goal was to reduce surgical site
infections at the hospital by implementing a nasal decolonization intervention of Staphylococcus
aureus before surgery.
Nursing care can directly affect long-term outcomes for patients. At a large Veteran’s
hospital on the West Coast, I undertook the opportunity as a clinical nursing leader (CNL)
student to create and implement an improvement project to reduce surgical site infection through
nasal decolonization of high-risk patients. The role of the CNL has evolved since its
introduction in 2007. As a microsystem expert, one of the strengths of the CNL is developing
quality improvement strategies which improve outcomes for patients without increasing the
burden on frontline staff. This improvement project incorporated expert knowledge of the
microsystem, patient preparation, and current evidence-based recommendations to create an
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intervention reduce SSIs through nasal decolonization for Staphylococcus aureus (S. aureus)
prior to surgery.
Clinical Leadership Theme
The Clinical Nurse Leader role embraces nine core competencies; advocate, member of a
profession, team manager, information manager, life-long learner, systems analyst/risk
anticipator, clinician, outcomes manager, and educator (American Association of Colleges of
Nursing, 2013). The theme for improvement was the reduction of surgical site infections (SSIs).
This quality improvement process incorporated advocate, team manager, outcomes manager and
educator competencies.
As an advocate, an opportunity to improve patient outcomes while reducing cost was
identified. Reducing surgical site infections supports a high quality of life and successful
surgical outcomes. As outcome manager, I designed and implemented a process to treat all
patients with a surgical incision to prevent deep tissue MRSA infections.
As outcome manager, I collaborated with a Clinical Nurse Specialist who is an SSI
reduction expert. It was critical that all disciplines understood and executed their roles in the
process. In accordance with CNL Competency 2.2, “Assume a leadership role of an
interprofessional healthcare team with a focus on the delivery of patient-centered care and the
evaluation of quality and cost-effectiveness across the healthcare continuum” (American
Association of Colleges of Nursing, 2013, p. 10), the new process was developed and
implemented with support. As a CNL student I coordinated with the commodities committee to
obtain the product needed for implementation, and with Information Technology (IT) to create
documentation to reflect the intervention performed.
As an outcome manager, I used baseline data to select opportunities for improvement in
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the microsystem. I monitored charts to evaluate completion of the intervention and
documentation. I followed the SSI rates and assessed the efficacy of the intervention to
determine the next steps, if needed, to improve MRSA SSI rates. This aligns with CNL
Competency 3.1, “Use performance measures to assess and improve the delivery of evidencebased practices and promote outcomes that demonstrate delivery of higher-value care”
(American Association of Colleges of Nursing, 2013, p. 12).
For the implementation of the quality improvement project, I embodied the CNL
educator role in many ways. Before implementation I developed teaching aides for
implementation to aid in the proper use of the chlorhexidine wipes and povidone-iodine nasal
swabs (see Appendices A and B). I prepared and presented a 15-minute seminar on surgical site
infections, present hospital SSI rates, existing interventions, and proposed changes. For the first
week of implementation I was present and available for staff to answer questions and problemsolve when necessary.
The decontamination process began with testing patients for MRSA in the pre-op
clinic. The process ended 30 days after surgery for patients without an implant and 90 days after
surgery for patients with an implant. The process identified patients with nasal methicillinresistant Staphylococcus aureus (MRSA) colonization, assured appropriate antibiotics were
selected for a surgical procedure, and standardized intervention prior to surgery to ensure all
patients receive the same standard of care.
Statement of the Problem
Prior to the implementation of the project the practice for cardiac and orthopedic
preoperative patients at the medical center was routine screening for MRSA colonization via
nasal swab one to four weeks prior to surgery. Patients who were MRSA-positive were treated
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with mupirocin ointment to nares and chlorhexidine showers for five (5) days prior to surgery.
Despite interventions to reduce SSIs, SSI rates had increased in these populations.
At the medical center compliance with the protocol had been challenging at every step;
patients were not always seen more than seven (7) days prior to surgery, positive screens did not
consistently result in provider action, the medication did not always arrive in time, and patients
did not reliably follow instructions. When a patient arrived on the day of surgery and had not
received treatment the decision was left to the attending surgeon to cancel or move ahead
without decolonization.
Project Overview
The goal of the project was to identify and implement a practical decolonization protocol
for high-risk veteran populations undergoing surgery. The Operative Care Division (OCD) and
the Infection Control Clinical Nurse Specialist (CNS) partnered to identify a practical
decolonization protocol for high-risk veteran populations. I implemented the rollout of the new
protocol. Moving forward, the CNS will monitor and report quarterly on SSI rates for both
populations.
The process involved nurses in three distinct practice areas: pre-op clinic, pre-op holding,
and the operating room, as well as surgeons and the operating room pharmacist. The initiation of
povidone-iodine (PI) treatment commenced May 15, 2017. Screening for nasal colonization of
MRSA began June 27, 2017.
The initial plan was initiated as an evidence-based best practice recommendation to
reduce SSIs by treating each preoperative patient with chlorhexidine washcloths, oral
chlorhexidine rinse, and intranasal PI solution the evening before surgery and on the day of
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surgery (Bebko, Green, & Awad, 2015). Due budget constraints for supply purchases and staff
ability to provide bedside baths on the day of surgery the intervention needed to be scaled back.
The first intervention initiated was to test all “patients except eye surgery and endoscopy
patients” attending the preoperative readiness clinic for MRSA by nasal swab. If patients tested
positive, they received Vancomycin, as opposed standard cephalosporin such as Cefazolin (Rao
et al., 2011). This intervention was driven by the operating room pharmacist, who partnered to
help reduce surgical site infections.
Initiation of the MRSA testing required education of the preoperative readiness clinic to
identify patients and enter orders for each patient. On the day of surgery the admitting nurse
verified that the patient had bathed with chlorhexidine. If the patient had not, the patient
received a chlorhexidine bath at the bedside. All indicated patients received the intranasal PI
within two hours of surgery. The staff documented the intervention in the pre-op holding note.
The exceptions to treatment are: patients who are allergic to povidone-iodine, patients having
surgery at the site of application, or those who refuse treatment. Patients who bypass the pre-op
holding area are treated with intranasal PI in the operating room by the circulating RN.
To meet the primary goal several objectives were created, each one opening a door for
successful project development and implementation. In the pre-op clinic, the objectives included
identification of patients requiring MRSA swab for the pre-operative clinic visit and ensuring
patients understood the importance of and process for pre-operative showers (see Appendix A).
In the pre-op holding area the objectives included obtaining the needed PI swabs, creating
educational posters to support staff training (see Appendix B), training staff to provide the PI
intranasal intervention, and identifying patients requiring PI swab the day of surgery.
There is also a cohort of patients that bypasses the pre-op holding area. These patients
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include emergent operations, after-hour cases, and patients originating in the Intensive Care Unit.
It was necessary to make certain that these patients also received PI treatment to address all
patients undergoing surgery and ensure successful implementation. The strategies to accomplish
this included training staff to provide the PI intranasal intervention, providing the PI swab in a
convenient storage area, and providing an efficient process to chart the intervention.
The final goal was the creation of a Standard Operating Procedure (SOP) regarding preoperative interventions to reduce SSIs and to promote the adoption of the intervention over time.
Rationale
Reducing surgical site infections is currently a Joint Commission patient safety goal on
which hospitals report (The Joint Commission, 2016). At the medical center the Infection
Control Department collects data on all SSIs at the hospital and reports the rates quarterly; the
data can be accessed on the hospital’s intranet. Despite current interventions, SSI rates continue
to increase. Critically evaluating current interventions including contributing causes (see
Appendix C) can assist in identifying weaknesses within the microsystem and macrosystem and
opportunities to create improvement interventions.
SSIs are extremely costly; the cost of treating a single surgical site infection is reported to
range from $26,000 to $250,000, with direct hospital costs averaging $117,411 per infection
(Courville et al., 2012). However, the most compelling reason to implement this improvement
project is that outcomes after SSI with joint surgery are often not equal to the successful
functional outcome of an uncomplicated surgery (Courville et al.).
Cost-benefit analysis can demonstrate cost savings associated with a proposed process
improvement project (Penner, 2017). In the case of this demonstration project, the hospital
allocated $5,000 for labor and $70,000 for materials for the first year. The labor costs covered
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100 hours of CNL time at the cost of $50 per hour. The materials needed were a sufficient
supply PI swabs to treat a projected 5,000 patients. The on-going cost to maintain the protocol is
projected to be $70,000 per year for subsequent years. After initiation of the process the
application of the PI is expected to become standard practice while preparing a patient for
surgery and to require no additional staff support.
In fiscal year 2016 the hospital reported 13 MRSA SSIs. If this improvement project
meets its goal of reducing MRSA SSIs by 10%, this will avoid an average of 1.3 infections per
year, with an associated cost savings of $117,411 per infection. This cost savings alone fully
justifies the expense associated with the change in protocols.
Additionally, a reduction in SSIs yields an improvement in patient quality of life. Quality
of life is significantly and negatively affected when a patient experiences an SSI, especially for
patients with implanted hardware. Patients who experience deep SSIs report lower quality of life
and pain. (Andersson, Bergh, Karlsson, & Nilsson, 2010). Patients experienced decreased work
productivity, lower functional capabilities, and require months of antibiotic therapy and
rehabilitation services (Courville et al). While these costs are primarily borne by the patient,
their reduction should be considered to be of benefit to the medical center as well.
Methodology
Lippett’s change theory was chosen as the theoretical framework for this project aimed at
reducing surgical site infections (SSIs).
As described by Mitchell (2013), Lippett’s change theory (1958) has seven phases:
•

phase 1, identify the problem;

•

phase 2, assessment of motivation and capacity for change;

•

phase 3, assess if the change agent has the resources and impetus to make the
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change;
•

phase 4, select an objective, develop an action plan;

•

phase 5, determine the role of the change agent with clearly defined expectations;

•

phase 6, sustain the change;

•

phase 7, the change agent should remove themselves over time, and the sustained
change will become part of the established norms;

Kritsonis (2005) describes Lippett’s change theory as an extension of Lewin’s three
phases of change (1951); freezing, changing, and unfreezing, taking the basis of purposeful
intervention for change and emphasizing the accountability of the change agent. As Mitchell
(2013) described, Lippett’s change theory aligns with nursing process; assessing the problem,
making a plan to improve the problem, implement interventions, and evaluating efficacy. This
makes it an especially appropriate framework to use in this project as it builds upon an already
familiar and relatable process. Therefore an action plan for implementation of the change
strategy was identified. (See Appendix B for a visual roadmap).
Phase 1 began in July 2016, when the workgroup identified the need to revise the nasal
decolonization protocol prior to surgery. During phase 2, a higher-than-desired SSI rate
motivated the workgroup to research and develop improved protocols, with the goal of providing
better care for veterans by reducing SSI rates and thereby improving surgical outcomes. In phase
3 I determined professional resources available. A mentor and hospital leadership supported the
project, and a clinical need drove the change in protocol. During phase 4 I developed the AIM to
reduce S. aureus SSI rates by 10% for FY17, and the action plan to meet the AIM. (See
Appendix D for the specific action plan.) In phase 5 the workgroup determined that I would be
leading the project, with the overwhelming support of all the other team members.
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I was tasked with determining how the existing protocol needed to be changed, creating
the new protocol, procurement of all necessary supplies, updating all relevant documentation,
educating staff and overseeing the final rollout. For phase 6, which began in May 2017, sustained
change was supported by active monitoring of supply levels to ensure adequate stock of all
needed materials, regular check-ins with frontline staff to verify compliance with the new
protocol, and on-going communication with the surgeons to maintain awareness of the change
and to remind them of the benefits both to their patients and to themselves.
Upon successful implementation of the new protocol (phase 7), the workgroup will meet
in November 2017 for a final debriefing session, after which the new protocol is expected to be
self-sustaining. Regular monitoring of SSI rates will confirm the value and efficacy of the new
protocol, reinforcing both its desirability and staff compliance. The Infection Control
Department tracks and reports all MRSA surgical site infections that occur at the medical center.
In future years MRSA SSI rates will be compared quarterly to evaluate the intervention efficacy.
Data Source/ Literature Review
The focus of this project was a specific intervention to reduce SSIs. In a
multidimensional problem such as this, interventions were required at multiple points along the
care continuum. The focus of this project was to implement a practical decolonization protocol
for high-risk veteran populations undergoing surgery, and to do so using evidenced-based
practice recommendations to decrease the occurrence of SSIs.
The PICO used was: P: Surgical patients at risk for S. aureus surgical site infection, I:
Standard decolonization treatment of five days nasal mupirocin and five days of chlorhexidine
body wipes, C: Decolonization with nasal PI day of surgery, O: Reduced S. aureus surgical site
infection rates. A search of the PubMed database conducted using a PICO search strategy
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of povidone-iodine, prevention of surgical site infections, and nasal yielded 12 articles with dates
from 2012-2017. Six quantitative studies were selected for review.
A search of the CINHAL database conducted using a PICO search strategy of povidoneiodine, prevention of surgical site infections, and nasal yielded 15 articles with dates from 20122017. Five quantitative studies were selected for review. The selected articles described
treatments to reduce S. aureus SSIs.
Search strategies that did not yield desired articles included morbidity, morality,
and surgical site infection, best practice surgical site infection.
The literature supports a multifaceted approach to successfully preventing surgical site
infections. The authors reported that there are four types of wound classification when surgery is
performed; clean, such as a joint replacement, clean-contaminated, such as uncomplicated
appendectomy, contaminated such as a ruptured appendectomy, and dirty, such as an incision
and drainage of an abscess. Risk factors for infection included virulence, wound environment,
and patient risk factors including an infective load that could be modified with pre-operative
antibiotics and MRSA decolonization.
Measures to decrease the incidence of SSI included preoperative, surgical, and
postoperative measures. Preoperatively, preoperative antibiotics, bowel preparation (if
indicated), preoperative showers, preoperative hair removal conducted in a manner not to shave
the skin, nasal decolonization for MRSA carriers, and operative staff adhering to dress code and
hand decontamination protocols were recommended. During surgery, preoperative antibiotics
were given prior to incision, prepping the skin with chlorhexidine, and the use of antimicrobial
sutures was recommended. Postoperatively, proper nutrition, effective glycemic control, aseptic
wound care, and proper oxygenation were shown to decreased rates of surgical site infections.
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The literature presently supports two techniques for nasal decolonization. Anderson, M.J.
et al. (2015) demonstrated PI is successful in treating mupirocin-resistant strains of S. aureus.
Four experiments were performed to evaluate the efficacy of nasal mupirocin and nasal PI on
MRSA colonization of tissue. In the two ex-vivo experiments healthy tissue was exposed to
MRSA and treated with betadine or mupirocin ointment. The third experiment was performed
on healthy human subjects. This experiment involved a baseline MRSA swab test followed by
control solution or povidone preparation, after which swabs of the normal flora of the anterior
nares were attained at 1, 6, and 12 hours. The final experiment was performed on MRSA
infected explants receiving treatment with PI, mupirocin, or no treatment. All revealed
significant finding of treatment versus control group. Clinical implications of the study
concluded that the best preventative treatment of potential S. aureus SSIs in surgical populations
is PI nasal treatment.
Also, Phillips et al. (2014) demonstrated that a single treatment of nasal PI yields superior
results to 7-10 mupirocin treatments over five days. Patients undergoing spinal or orthopedic
joint surgery (N=1874) were randomized into mupirocin or PI treatment groups. Findings
suggested a significant reduction in S. aureus in the mupirocin group versus iodine alone (P=03).
The author advocated the use of PI as a superior choice based on cost and patient outcome.
Surgical site infections have physical, emotional and financial implications. Andersson,
A. E., et al. (2010) reported on a qualitative research study in which 14 patients with deep
surgical site infections were interviewed. This study investigated the patient's quality of life after
experiencing a deep tissue SSI. The patients reported on three themes; the emergence of the
problem, a period of pain and fear of the potential outcomes of the infection, and the impact on
their lives and the need to adapt to their disability. Patients reported that their deep SSI had
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affected physical, emotional, social, and economic aspects of their life. Pain from the SSI site
was reported as a finding in most patient reports. Patients reported that the most significant
outcomes they were seeking after SSI occurrence were pain relief, improved function, and
improved quality of life.
Dohmen, P. M.(2013) also explored the economic impact of surgical site infection after
cardiac surgery. The direct costs of prolonged hospital stays, additional surgery, needed
treatment for infection, and medications were estimated to be $1,084,63 for a single deep-tissue
SSI. Indirect costs including loss of income by patient or family, loss of quality of life, and cost
incurred traveling to seek care. The indirect costs of an SSI were estimated to be 800% of the
direct costs.
There are many approaches to preoperative reduction of surgical site infections. Bebko, et
al. (2015) describes an evidence-based approach to reduce surgical site infections in patients
undergoing elective orthopedic surgery with hardware implantation. The prospective study
included 709 patients, 344 in the control group and 365 who received decolonization. The
decolonization group interventions included a chlorhexidine washcloth bath and oral
chlorhexidine rinse the evening before surgery, a repeated bath and oral rinse the morning of
surgery, and an application of intranasal PI on the day of surgery. The control group surgical site
infection rate was 3.8%, compared to the decolonization group rate of 1.1%. The reported results
represent a more than 50% reduction in surgical site infections in the experimental group.
Other concerns when selecting an intervention is patient tolerance of the intervention.
Maslow, Hutzler, Cuff, Rosenberg, Phillips, and Bosco (2014) explored patient experience of
preoperative nasal decolonization. Patients were randomized prior to surgery to self-administer
five days or nasal mupirocin or receive nasal PI administered by staff within two hours of
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surgery. Of the patients (N=1903) 88.1% were interviewed prior to discharge. Adverse
reactions reported from both groups were; a headache, rhinorrhea, lung or throat congestion,
pruritus, and sore throat. Participants who received PI reported lower rates of adverse reactions
(P<.05) except pruritus (P=.193). Of the patients who received mupirocin, 38.8% reported
having an unpleasant or very unpleasant experience, compared to 3.4% of patients receiving PI
(P<.0001). Clinical implications of this study conclude that nasal PI can be considered better
tolerated than nasal mupirocin for preoperative nasal decolonization.
When selecting an intervention another concern is cost. Torres, Lindmar-Snell, Langan,
and Burnikel (2016) compared the cost of nasal mupirocin and nasal PI for preoperative nasal
decolonization. Two consecutive cohorts were used. The first cohort was screened for MRSA,
and if positive, patients received five days of nasal mupirocin and five days of chlorhexidine
showers. In the second cohort, no MRSA screen was performed, and all patients received five
days of chlorhexidine showers and a single treatment of nasal PI. Two findings suggested no
difference in infection rates (P=1). The cost per patient for nasal mupirocin was $116.19 while
the cost per patient for nasal PI was $16.42. Clinical indications from this study conclude nasal
PI treatment is less expensive than nasal mupirocin, with comparable SSI outcomes.
In conclusion, this research indicates that a single step treatment of nasal PI has
equivalent or better results than mupirocin ointment to nares for five days prior to surgery.
Furthermore, benefits included less likelihood of the development of antibiotic resistance, greater
patient compliance with the treatment, decreased cost, and lower incidence of SSI development.
Timeline
Creating a timeline can be helpful to maintain momentum and provide a guide to
completion. A successful timeline captures the essential steps in chronical order and also tracks
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the journey over time. The timeline also serves as a reminder to re-center if the process gets off
track. See Appendix J for a visual timeline to implement nasal decolonization prior to surgery to
decrease surgical site infections.
Expected Results
The expected results are a decrease in the incidence of MRSA surgical site infections at
the medical center. Although the originally proposed intervention included all of Bebko et al.’s
(2015) recommendations to add oral chlorhexidine and a chlorhexidine wipes rinse the evening
before surgery, along with a repeated bath, oral rinse, and an application of intranasal PI at the
bedside on the day of surgery due to cost and staff availability full initiation of the described
protocol was not feasible. If the results do not meet the AIM, the SSI improvement workgroup
will recommend adding more Certified Nursing Assistants (CNAs) to allow for additional
interventions to improve SSI rates.
Nursing Relevance
This nurse-driven process improvement project is intended to identify a cost-effective
and practical decolonization protocol that will improve patient outcomes and avoid hundreds of
thousands of dollars in medical expenses. This improvement project is an example of evidencebased practice (EBP) change guided by Lippett’s change theory. EBP changes support the
translation of new knowledge from idea to implementation to provide improved care with betterquality outcomes (Lockwood & Hopp, 2016). Frontline nursing staff are the eyes and ears
process improvement. They have valuable insight into how processes can be improved, and the
ability to influence their practice. Nurses using horizontal leadership strategies to support small
changes at the bedside can create big-picture changes.
Developing nurse-driven procedures that meet national patient safety goals, improve
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patient care, and patient outcomes demonstrate the importance of the transformation of nursing
practice. We nurses are the face of nursing to our patients. Setting the expectation that frontline
staff are experts in their care and are continually improving care is the gold standard for excellent
care in healthcare today. The relevance of this project is two-fold; to decrease the incidence
patient experiences of life-changing medical sequelae, and to demonstrate the effectiveness of
nurse-driven change to improve care. Future change agents can use this process improvement
strategy as a framework for their projects.
Summary
The objective of this nurse-driven process improvement project was to implement a costeffective and practical decolonization protocol to improve outcomes for high-risk veteran
populations undergoing surgery at a large veteran’s hospital in the Pacific Northwest. The AIM
was to reduce S. aureus SSI rates by 10% for FY17. During the process of the project the AIM
was further refined to MRSA SSIs based on current data collection processes. The population is
all surgical patients except eye surgery patients, endoscopy patients, and patients having surgery
at the location of the intranasal treatment.
The original AIM was to reduce all SSIs, and the intent will be to minimize infections for
all surgeries. Data for SSIs are collected by the Infection Control Department. Data are
collected for all MRSA infections, coronary artery bypass, implanted hardware orthopedic
surgery, implanted hardware craniotomy neurosurgery, and colon surgeries. Constraints in
existing data collection and difficulty in capturing SSI information not being currently collected
caused me to choose to adjust the AIM to ensure accurate data collection and reporting.
Implementation of the project had three distinct phases. Baseline data (see appendix K)
provided evidence that a new intervention is needed to address rising rates of MRSA SSIs. The
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first phase, involved planning for all three phases, determining who to test, what interventions to
implement, and how to disseminate information about the chosen interventions to hospital staff.
I found the first phase to be the most challenging, in particular defining roles for
participants and obtaining successful buy-in in the project. Testing for MRSA in the pre-op
clinic for all surgical patients added two tasks for the LPN’s of the clinic. The LPN would have
to add the order to the electronic medical record and then perform the test. The staff was very
comfortable with performing the lab test, but adding orders proved more challenging.
This element of the project required additional steps, including requesting the staff access
to order the test in the electronic medical record and teaching the staff how to enter the order
correctly. Although not difficult, staff expressed anxiety with this task and required written and
multiple in-person education to successfully complete this step.
The next step was to create a sense of urgency among the staff involved. I developed a
presentation which included the current SSI results and EBP recommendation, along with the
proposed changes at the medical center. The infection control CNS attended each presentation to
support the project and answered specific questions about hospital data. I gave presentations
pre-op clinic staff, Operative Care leadership, surgeons, the pre-op day of surgery staff, and the
operating room staff.
The second phase involved implementing the intervention. Requesting the PI swab
through commodities involved completing a request form, explaining the need for the product.
Approval of the request required gaining approvals from the Division Director, the Commodities
Committee, and the Service Chief overseeing the Commodities Committee. The approval
process took a total of two months. I was told that was impressively quick compared to previous
requests.
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The next task was to work with logistics to locate a good place to store the swabs which
was accessible to the staff. I also created the educational reference (see Appendix B). I chose to
use a well-respected staff member for the demonstration photograph to encourage staff buy-in.
This proved to be a successful strategy; I received many positive comments about his
participation. In healthcare, if it isn’t documented it isn’t done. The final, crucial step was
creating a simple way to document the intervention without creating additional work for the staff
(see Appendix L). The documentation is two additional clicks in the existing note the nurses
already utilize.
I was not scheduled into the staff mix on the first implementation day to ensure a
successful rollout, this allowed me to be present to support the staff but not take a patient load. I
recruited the PI company representative to be present for the first week of implementation to
offer support with the application, if necessary. After implementation I recruited staff members
to participate in chart review of documentation and patient compliance. After 12 weeks of
implementation, preliminary chart review and MRSA SSI results were presented to the group
and a competency form was distributed and completed by staff (see Appendix M). Staff was
given an opportunity to ask questions about the process and to provide feedback. I am pleased to
report that feedback from staff was positive.
In the second phase, we identified patients who did not go the through the pre-op holding
area. Those patients include ICU patients, urgent patients, and patients treated outside of normal
working hours. Including these patients in the process became phase three of the project. This
phase entailed educating the OR staff, partnering with the Assistant Nurse Manager of the OR to
included identical charting in the OR nurses charting standard charting review of chart
compliance with the new intervention by the OR nurses. Chart review of 10 weeks of
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documentation revealed compliance rate of 52% (see Appendix N). The next step will be
targeted re-education to increase compliance.
After review of the first 16 weeks of charting since implementation, compliance with the
intervention was found to be 90% (see Appendix O). I had expected a reduction, as stated in the
AIM, a 10% reduction, which would be one or two fewer infections. The results are better than
expected as no MRSA SSIs have been reported since the implementation of the intervention.
This represents a 62% decrease from FY17 (see appendix K). It has been seven months since
initial implementation, with Lippett’s change theory the final step is that the sustained change
will become part of the established norms after the change agent removes themselves. On any
given day, you can walk into the pre-op holding area, and hear the staff, explaining and
performing the intervention. I feel very accomplished that chart review reveals high compliance,
and the intervention has been adopted by the staff as has been “normal practice”.
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Povodine-Iodine Internasal Application Instructions
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Appendix E

Adapted from Mitchell, G. (2013). Selecting the best theory to implement planned change. Nursing

Management - UK, 20(1), 32–37
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Appendix J
Detailed Timeline for Implementation
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Appendix K
Reported MRSA Surgical Site Infections 2010-2017

Total Number of MRSA Surgical Site Infections (SSI)
by Fiscal Year (FY) 2010 - 2016
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Documentation of Povidone Iodine Intranasal swab in Electronic Medical Record
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Appendix O
Documentation and Patient Compliance in Pre-op Holding
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